Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Surrozen, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics that selectively activate the Wnt signaling pathway, a biological pathway critical to tissue repair and regeneration. The company operates within the biotechnology and life sciences industry, with a strategic emphasis on gastrointestinal, inflammatory, and metabolic diseases where epithelial tissue damage is a core driver of disease progression.
The company’s primary revenue drivers are research and development activities related to its proprietary Wnt pathway modulation platform and its pipeline of preclinical and clinical-stage drug candidates. Surrozen does not currently generate product sales revenue and relies on capital markets, partnerships, and prior collaborations to fund operations. The company was founded in 2019 through a spin-out from Samumed, LLC, a privately held biotechnology company, and became a publicly traded entity following its initial public offering in 2021.
Business Operations
Surrozen operates as a single reportable business segment focused on research and development of biologic therapeutics. Its core assets include engineered antibodies and fusion proteins designed to activate Wnt signaling in a tissue-specific and controlled manner. Key pipeline programs have targeted conditions such as ulcerative colitis and other inflammatory bowel diseases, leveraging the company’s internally developed SWAP™ (Surrozen Wnt signal Activating Protein) platform.
Operations are primarily based in the United States, with no commercial manufacturing or sales infrastructure. The company controls its intellectual property portfolio internally and conducts development through a combination of in-house research and outsourced preclinical and clinical activities. Surrozen has historically engaged in collaboration and licensing arrangements, including legacy agreements originating from its separation from Samumed, LLC, though it currently operates independently without disclosed active joint ventures.
Strategic Position & Investments
Surrozen’s strategy centers on advancing its Wnt-pathway-based therapeutics through early- and mid-stage clinical development while managing capital efficiency. Growth initiatives have included prioritizing lead clinical assets, restructuring internal operations, and selectively advancing pipeline candidates with the highest probability of clinical and commercial impact. The company has also undertaken workforce reductions and program prioritization to extend its cash runway, reflecting broader market conditions in the biotechnology sector.
The company’s investments are concentrated in its internal pipeline rather than external acquisitions. Surrozen does not maintain a diversified portfolio of subsidiaries; instead, it operates as a focused development-stage entity. Its strategic positioning is differentiated by its proprietary approach to Wnt activation, which aims to avoid safety concerns historically associated with systemic Wnt signaling while enabling regenerative effects in targeted tissues.
Geographic Footprint
Surrozen is headquartered in the United States, with its principal offices located in California. Its operational footprint is primarily domestic, reflecting its status as a clinical-stage company without commercial distribution. Research activities, corporate management, and development oversight are centralized at its U.S. facilities.
International exposure is limited and indirect, primarily through the use of global contract research organizations and potential future clinical trial sites outside the United States. The company does not currently report material international revenue or owned facilities outside North America.
Leadership & Governance
Surrozen is led by an executive team with experience in biotechnology development, clinical research, and corporate strategy. The company’s leadership emphasizes disciplined capital allocation, scientific rigor, and advancing targeted regenerative therapies through well-defined clinical milestones. The company originated from technology developed at Samumed, LLC, rather than from an individual founder-led structure.
Key executives include:
- Craig Parker – President and Chief Executive Officer
- Alfred W. Sandrock Jr., MD, PhD – Chief Medical Officer
Data regarding additional executive appointments or changes beyond these roles is inconclusive based on available public sources.